Young HIV Positive People Respond Well to HPV Vaccine

Young HIV Positive People Respond Well to HPV Vaccine

The study, Presented at the International AIDS Conference in Melbourne Last Week, Showed that the HPV Vaccine Works Just as Well for HIV-Positive Patients as it Does for HIV-Negative People Human Papillomavirus, the most common sexually transmitted infection, occurs in a variety of strains that vary in severity. People will typically become infected with HPV after they have become sexually …

Scripps Institute One Step Closer to HIV Vaccine

The Scripps Research Institute (TSRI) identify single surface protein site for HIV vaccine. Following a study on the possibilities of directing a vaccine at a single site on a surface protein of HIV, The Scripps Research Institute (TSRI) believes it may be able to develop a vaccination capable of neutralizing nearly all strains of the virus. Led by TSRI Professor …

Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies

Study Published in Immunity in Collaboration with The Scripps Research Institute and IAVI April 25, 2014 Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the publication of data in the May issue of Immunity regarding antibodies with significant potency and breadth against human immunodeficiency virus (HIV). The study, titled “Broadly neutralizing HIV antibodies define a novel glycan-dependent epitope on the …

How To Make A HIV Vaccine

This week marked 30 years since the public announcement that the cause of AIDS had been discovered. But how close are we to defeating HIV? And what sort of vaccine will help us to do this? Well there are a number of different approaches to the creation of a HIV vaccine, some of which look to stop patients from contracting …

HIV & AIDS: Facts, figures, and vaccines

This month on Vaccine Nation we’re going to be taking a look at HIV/AIDS vaccines. In the coming weeks we will  look at the current generation of HIV vaccines and the different approaches developers are taking in their attempts to defeat this notorious virus. (The infographic may take a few seconds to load) If you have trouble viewing this inforgraphic …

NIH Awards Seattle BioMed $9.8m to Develop HIV/ AIDS Vaccine

Seattle BioMed Awarded $9.8 Million Grant from the National Institutes of Health to Develop Vaccine Against HIV/AIDS March 10, 2014 Seattle BioMed today announced that it has received a seven year Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine that would elicit broadly neutralizing antibodies against HIV-1. …